fbpx
Medical Innovation Exchange

CytomX slashes headcount by 40% after breast cancer setback, with later-stage development bearing the brunt

https://www.fiercebiotech.com/biotech/cytomx-slashes-headcount-40-after-breast-cancer-setback-later-stage-development-bearing

Leave a Comment

Your email address will not be published.

Leave the field below empty!

This site uses Akismet to reduce spam. Learn how your comment data is processed.